| ||
| Quality of Life Significantly Improved with Erlotinib for NSCLC Monthly Prescribing Reference CHICAGO—Erlotinib improved progression-free survival (PFS) when compared with gemcitabine + carboplatin (GC) as first-line treatment for EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer, according to the results of ... See all stories on this topic » | ||
| ||
| ||
| Crizotinib improved survival in advanced, ALK-positive NSCLC HemOncToday CHICAGO — Results from an analysis of patients with advanced, ALK-positive non-small cell lung cancer showed that those treated with crizotinib had superior OS when compared with historical controls. Though the results are promising, Alice T. Shaw, MD ... See all stories on this topic » | ||
| Pemetrexed maintenance therapy prolonged PFS in advanced NSCLC HemOncToday CHICAGO — Continuation maintenance therapy with pemetrexed improved PFS in patients with advanced nonsquamous non-small cell lung cancer who also received the chemotherapy drug during their initial treatment regimen, according to study results ... See all stories on this topic » | ||
| Why pregnancy and cancer are dangerous duo msnbc.com The researchers compared changes in gene expression in the pregnant mice to changes in gene expression in human lung cancer patients. They found that the same genes that had decreased expression in pregnant mice also had decreased expression in the ... See all stories on this topic » | ||
| US Stock Futures: HOT STOCKS TO WATCH Wall Street Journal Shares of Oxigene rose 11% to $4.73 premarket after reporting encouraging data in a Phase II trial of Zybrestat in non-small cell lung cancer on Saturday. The biotech's shares had rallied sharply on Friday ahead of study presentations expected over the ... See all stories on this topic » | ||
| The RegMed Daily Dialogue - The June Swoon is ON Proactive Investors USA & Canada GERN's P2 clinical program for imetelstat includes 4 clinical trials – 2 randomized clinical trials in non-small cell lung cancer and breast cancer, and 2 smaller single arm studies in multiple myeloma and essential thrombocythemia. ... See all stories on this topic » | ||
| Biotech News Break; Exelixis Stock Review Beacon Equity Research The company reported that of the nine tumor types included in the RDT, a week-12 disease control rate of 40% was seen in the melanoma, hepatocellular cancer, breast, prostate, ovarian and non-small cell lung cancer. Exelixis also reported over the ... See all stories on this topic » | ||
| Roche's Pricy Avastin May Slow Ovarian Cancer Progression Medical News Today Avastin received its first approval in 2004 for combination use with standard chemotherapy for metastatic colon cancer and non-small cell lung cancer. In 2008, it was approved by the FDA for use in metastatic breast cancer, a decision that generated ... See all stories on this topic » | ||
| Foundation Medicine Announces Results Using Next-Generation Sequencing to ... Business Wire (press release) This test has the potential to significantly benefit the medical community and cancer patients by informing optimal cancer therapy selection." The study evaluated DNA extracted from 75 cancer tissue samples in three cohorts (non-small cell lung cancer ... See all stories on this topic » | ||
| Novartis' Gleevec Cancer "Magic Bullet" Extends Life In GIST Patients Medical News Today In contrast, most of the "common" cancers, such as lung cancer, skin cancer, and prostate cancer, are derived from a different type of cell, known as "epithelial cells", the cells which line the body's many surfaces. Why does this distinction matter? ... See all stories on this topic » | ||
| Studies Focus On Cancer As A Chronic Disease Medical News Today (press release) ... maintenance therapy with the chemotherapy drug pemetrexed (Alimta) improves progression-free survival (PFS) in patients with advanced nonsquamous non-small cell lung cancer who also received pemetrexed as part of their initial chemotherapy regimen. ... See all stories on this topic » | ||
| Teva Says Phase III Study Of Lipegfilgrastim In Breast Cancer Met Primary Goal RTT News An additional efficacy and safety study comparing lipegfilgrastim to placebo in preventing chemotherapy-induced neutropenia in non-small cell lung cancer patients is currently ongoing, with results expected later this year. by RTT Staff Writer. See all stories on this topic » | ||
| Exelixis Zeroes in on Lead Drug, Sees Activity in the Bones of Prostate Cancer ... Xconomy Based on this study, prostate and ovarian cancer have emerged as the two settings in which Exelixis has seen the most interesting results, Morrissey says. Small-cell lung cancer, pancreatic cancer, stomach cancer provided less convincing evidence, ... See all stories on this topic » | ||
| Oxigene spikes on lung cancer tests optionMONSTER Research (registration) The small drug developer reported encouraging results for its treatment of small-cell lung cancer. The company released data on the Phase 2 trial of the drug, Zybrestat, over the weekend ahead of this week's American Society of Clinical Oncology's ... See all stories on this topic » | ||
| Initial Phase 2 Results of Crizotinib Show Promise in Advanced ALK-Positive NSCLC Monthly Prescribing Reference ... improved symptoms and clinically meaningful antitumor activity in patients with pretreated ALK-rearranged metastatic non-small cell lung cancer (NSCLC), investigators reported during the American Society of Clinical Oncology's 2011 Annual Meeting. ... See all stories on this topic » | ||
| DNA Testing Spurring New Breed of Cancer Drugs CNBC.com The drug has been shown to aid patients whose tumors express the ALK gene, a culprit in less than 5 percent of non-small cell lung cancers. Even with that limited potential pool for the drug, its annual sales could reach $2.5-billion, according to a ... See all stories on this topic » | ||
| Alimta extends progression-free survival among patients in late-stage study Drug Store News Lilly said results of the phase-3 "PARAMOUNT" study of the injected drug Alimta (pemetrexed) extended progression-free survival in patients with nonsquamous nonsmall-cell lung cancer. The study focused on continuation maintenance when one of the same ... See all stories on this topic » | ||
| Immune cells link pregnancy and tumor spread EurekAlert (press release) Of clinical interest, the majority of genes downregulated in the lungs of pregnant mice were also expressed at lower levels in samples from lung cancer patients with poor prognosis than in samples from patients with better prognosis. ... See all stories on this topic » | ||
| US Stock Futures Down Before Apple Worldwide Developer Meeting Wall Street Journal Shares of Oxigene Inc. (OXGN) rose 5.6% in pre-open trading after on Saturday reporting encouraging data in a Phase II trial of Zybrestat in non-small cell lung cancer. The biotech's shares had rallied 30% on Friday ahead of study presentations ... See all stories on this topic » | ||
| Morning Market Movers Benzinga OXiGENE Inc (NASDAQ: OXGN) climbed 18.22% to $5.06. OXGN announced encouraging data on a potential treatment for non-small cell lung cancer. SunOpta Inc (NASDAQ: STKL) jumped 14.88% to $8.50. On CNBC's "Mad Money," Jim Cramer said that he likes STKL. See all stories on this topic » |
| ||
| Geron Highlights ASCO/AACR Joint Session ... - Investor Stem Cell By iCELL News Geron's Phase 2 clinical program for imetelstat includes four clinical trials – two randomized clinical trials in non-small cell lung cancer and breast cancer, and two smaller single arm studies in multiple myeloma and essential ... Investor Stemcell - http://investorstemcell.com/ | ||
| US Stock Futures Wobble; Apple's Jobs in Front – (AAPL, OXGN, GOOG ... By Kieth Wright Oxigene Inc. (NASDAQ:OXGN) added 7.26% in pre-open trading after on Saturday announcing heartening information in a Phase II trial of Zybrestat in non-small cell lung cancer. The biotech's shares had advanced 30% on Friday previous to ... USA Market News - http://www.usamarketnews.com/ | ||
| Roche and OSI's Tarceva shows impressive ability to stall lung cancer ... now part of Japan's Astellas (TYO: 4503), have presented impressive results from the first Phase III study with Tarceva (erlotinib) in Western patients with a genetically mutated type of advanced non-small cell lung cancer (NSCLC), ... thepharmaletter.com - http://www.thepharmaletter.com/ | ||
| The RegMed Daily Dialogue - The June Swoon is ON GERN's P2 clinical program for imetelstat includes 4 clinical trials – 2 randomized clinical trials in non-small cell lung cancer and breast cancer, and 2 smaller single arm studies in multiple myeloma and essential thrombocythemia. ... Proactiveinvestors USA & Canada website - http://www.proactiveinvestors.com/ |
| ||
| Diagnostic patterns of non-small cell lung cancer at Princess ... Diagnostic patterns of non-small cell lung cancer at Princess Margaret Hospital. - ASCO - The American Society of Clinical Oncology (ASCO) is the world's ... www.asco.org/ASCOv2/Meetings/Abstracts?&...abst... | ||
| What is Nonsmall Cell Lung Cancer? Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are grouped together and called "nonsmall cell lung cancer" (NSCLC). ... www.hivaids.com/lung/guide/u_nsclc.html | ||
| Secondary Lung Cancer From Breast Cancer | Secondary Lung Cancer ... There are 2 forms of lung cancer, cancer of tiny cell lung cancer and non-small ... Three common forms of cancer non-small cell lung cancer, squamous cell ... www-cancer.us/.../secondary-lung-cancer-from-breast-cancer/ | ||
| Should Large Cell Neuroendocrine Lung Carcinoma be Classified and ... Background: To compare the presenting and prognostic characteristics of patients with large cell neuroendocrine lung cancer (LCNELC) with those of patients ... www.oncologystat.com/.../Should_Large_Cell_Neuroendocrin... |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment